The Role of Regulatory T Cells in Pulmonary Arterial Hypertension

Wen Tian¹,²†, Shirley Y. Jiang²†, Xinguo Jiang¹,², Rasa Tamosiuniene¹†, Dongeon Kim², Torrey Guan¹, Siham Arsalane¹,², Shravani Pasupneti², Norbert F. Voelkel³, Qizhi Tang⁴ and Mark R. Nicolls¹,²*¹

¹ Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA, United States, ² Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States, ³ Department of Pulmonary Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴ Department of Surgery, University of California San Francisco, San Francisco, CA, United States

Pulmonary arterial hypertension (PAH) is a chronic, incurable condition characterized by pulmonary vascular remodeling, perivascular inflammation, and right heart failure. Regulatory T cells (Tregs) stave off autoimmunity, and there is increasing evidence for their compromised activity in the inflammatory milieu of PAH. Abnormal Treg function is strongly correlated with a predisposition to PAH in animals and patients. Athymic Treg-depleted rats treated with SU5416, an agent causing pulmonary vascular injury, develop PAH, which is prevented by infusing missing CD4⁺CD25highFOXP3⁺ Tregs. Abnormal Treg activity may also explain why PAH disproportionately affects women more than men. This mini review focuses on the role of Tregs in PAH with a special view to sexual dimorphism and the future promise of Treg therapy.

Keywords: regulatory T cell, pulmonary arterial hypertension, sexual dimorphism, right ventricle, estrogen

INTRODUCTION

The first classification of pulmonary hypertension (PH) was proposed in 1973 and is now defined as an increase in mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest, normal left atrial pressure and pulmonary vascular resistance >= 3 Wood units (1). This review focuses on PAH which is classified by World Health Organization (WHO) as Group 1 PH (1). PAH includes idiopathic or sporadic cases (IPAH), heritable cases (HPAH, describing patients with a family history or identified germline mutations), and associated forms (attributable to conditions like anorexigens, liver diseases, congenital heart diseases, and connective tissue diseases) (2). Heterozygous germline mutations in gene encoding for bone morphogenetic protein receptor 2 (BMPR2) account for 53-86% of the familial cases of PAH and 14-35% of patients with IPAH (3). Although clinical features of HPAH and IPAH are indistinguishable, patients with HPAH have an earlier disease onset with more severe hemodynamics (4). There is a strong sex-associated influence on the development of PAH, with an approximate female to male patients’ ratio of 4:1 (5). Although the incidence of PAH is higher in women, the estimated 5-year survival is less favorable in men (52% in men compared to 62% in women) (6). Regardless of the underlying etiology, patients with PAH exhibit similar pathological alterations including remodeling of the pulmonary arterioles driven by proliferation/dysfunction of both pulmonary arterial endothelial cells (PAECs) and smooth muscle cells (PASMCs), in situ thrombosis, increased pulmonary arteriole contractility, and enhanced inflammatory infiltrates (7–9).
PAH is a lethal cardiopulmonary condition characterized by pulmonary vascular remodeling and right heart failure (10). Drugs used to treat this disease primarily target pathologic vasoconstriction, but there is an additional rationale for treating immune dysregulation (9). Growing evidence indicates that abnormal Treg activity promotes the development of PAH, and accentuating the activity of these cells has therapeutic potential (9). Tregs play a vital role in maintaining immune homeostasis, fostering tissue regeneration, and limiting vascular injury (11–13). They protect against autoimmunity by dampening inappropriate responses to self-antigen (14). This defensive activity was first identified in mice lacking thymic-derived CD4⁺CD25⁺FoxP3⁺ Treg cells and in Treg-depleted animals which develop a constellation of autoimmune conditions including thyroiditis, diabetes, autoimmune gastritis, and inflammatory bowel disease (14, 15). Subsequently, numerous pre-clinical autoimmune models show that Treg defects are implicated in the development of autoimmune diseases and prevented by the adoptive transfer of Tregs (14). Other types of CD4⁺ regulatory T cells are also discovered including IL-10-producing type 1 regulatory T cells and TGF-β-producing T helper 3 cells (16, 17). Here, we only discuss the CD25⁺FoxP3⁺ Treg population given the broader and indispensable roles of these cells.

PAH-associated conditions exhibit Treg abnormalities (18). Furthermore, Treg dysfunction in PAH affects males and females differently and may arise because of pathogenic gene variants (e.g., mutations in BMPR2 and chronic vascular inflammation (18–20). Our group demonstrated that adoptive transfer of Tregs is effective in preventing pre-clinical PAH (21). Treg infusions restore immune regulation, reduce endothelial injury, impede PAH-mediated vascular remodeling, and prevent right heart failure (21, 22). Because Tregs can limit and potentially reverse pulmonary vascular disease, Treg infusions may become a viable treatment for this condition (23). This review explores how genetic and environmental cues may cause Treg abnormalities that exacerbate PAH and discusses how the restoration of Treg function may attenuate this life-threatening disease.

REGULATION OF TREG ONTOGENY, IDENTITY, AND FUNCTION

Anti-inflammatory CD4⁺CD25⁺FoxP3⁺ Tregs comprise approximately 5% of CD4⁺ T cells and develop primarily in the thymus (24–27). Genetic mutations (e.g., FOXP3, RAG1, and AIRE) (28) impact Treg thymic development and predispose individuals to autoimmune conditions. Continued expression of FOXP3 and sustained FOXP3 signaling are required for Tregs to maintain their lineage-stability and function, and FOXP3 expression is influenced by local tissue microenvironment and sex hormones (26). For example, FOXP3 may be turned on in conventional T cells (Tconv, CD4⁺FoxP3⁺) at peripheral inflammatory sites to promote Treg phenotype (pTregs) (29). High concentrations of interleukin-1 beta (IL-1β) as well as interleukin-6 (IL-6) may result in decreased FOXP3 and increased interleukin-17 (IL-17) expression in Tregs (exTregs) (30–32). Specifically, proinflammatory IL-6, in conjunction with IL-1 and IL-23, induces the expression of RORγt and IL-17 and suppresses FOXP3 thereby causing a genetic reprogramming in FOXP3⁺ Treg cells (33). Elevated IL-6 also promotes the methylation of a conserved CpG-rich island of FOXP3 gene and results in reduced gene transcription (34). Notably, IL-1β, IL-6, and IL-17 are elevated in PAH and contribute to Treg instability and pathogenic inflammation (35, 36). Additionally, Tregs can specialize into T helper-(Th-) like subsets expressing Th1, Th17, Th2, or Th22 markers and receptors that mimic and suppress Th1, Th17, Th2, or Th22 immunity, respectively (37).

Abnormalities in thymic development and Treg production may be related to the most common genetic mutations in PAH involving BMPR2 (38). Normal thymus development requires bone morphogenetic protein (BMP) signaling (39); thymic epithelial cell maturation requires BMP4 (a BMPR2 ligand) and the activation of FOXN1 transcription factor (40). Consequently, BMPR2 mutations may affect embryonic thymic BMP4 signaling and influence Treg development in early life. It is unknown whether patients with BMPR2 mutations have decreased Tregs or whether the impact of BMPR2 signaling may be more subtle, not affecting Treg numbers globally but rather subset percentages and function. In peripheral lymphoid tissues, BMPR1α sustains the expression of FOXP3 in pTregs and is required for the maturation and preservation of Treg cell phenotype while inhibiting the differentiation of pro-inflammatory Th1 and Th17 cells (41). Missense mutations of BMPR1B were identified in pediatric IPAH cases (42) suggesting that BMPR1B insufficiency may contribute to the imbalance between Treg and Th1/Th17 populations in PAH. Genetic and environmental factors that govern Treg development and functionality (43) may ultimately play a role in the predisposition to PAH after vascular injury.

PAH AND TREG ABNORMALITIES

The immune dysregulation observed in PAH may be attributable to Treg anomalies (9, 18). Tregs maintain immune homeostasis, and their deficiency predisposes individuals to autoimmune injury (13, 26, 44, 45). Just as failing Tregs are increasingly recognized in cardiovascular diseases, abnormalities in Treg number and function are also reported in PAH (18, 36, 46–49). Inflammatory pathologies are associated with poor clinical outcomes in PAH and underscore the importance of understanding Treg derangements (9). Extensive pre-clinical evidence from our group and others suggest that abnormal Treg activity may explain autoimmune and inflammatory features noted in PAH (Table 1). Treg numbers are reduced in PAH lungs but increased in the peripheral circulation, displaying reduced suppressive functionality (46, 47, 77, 78). In addition to the thymic anomalies, defective leptin and adiponectin signaling may also influence Treg function in IPAH patients (46, 79).

The heterogeneous vascular lesions of PAH reveal numerous inflammatory cell types in and around the pulmonary vessels,
suggesting a coordinated immune response (9, 80). Treg abnormalities may promote the development and progression of PAH by failing to quell this inflammation following vascular injuries, such as that induced by shear stress, hypoxia, ischemia, or pathogens; the result, a prolonged and destructive period of vascular wound healing (9, 18, 20, 21, 81, 82). Beyond the regulation of adaptive immunity, Tregs control innate responses following injury. In a Treg-deficient model of PAH, we show that the absence of Tregs contributes to the emergence of destructive macrophage-based immunity culpable in progressive endothelial damage and vascular remodeling (83). Tregs can also control neutrophilic infiltration and preserve endothelial barrier function, possibly relevant to the pathogenesis of PAH (84, 85).

**MODELING TREG BIOLOGY IN PAH**

Aberrant Treg activity predisposes animals to vascular inflammation and PAH (86). We initially noted a predisposition to severe PAH in animals lacking normal T cells (athymic rats) after exposure to SU5416, a vascular endothelial growth factor 2 (VEGF2) receptor antagonist that causes pulmonary arteriolar injury. [Rats robustly model PAH in a manner not uniformly observed in mice (87)]. Treg-deficient rats exposed to SU5416 demonstrate an accumulation of B cells and macrophages after one week before developing hemodynamically-significant PAH (21). Restoring missing CD4\(^+\)CD25\(^{hi}\)FOXP3\(^{+}\) cells through intravenous infusion limits inflammation, prevents endothelial apoptosis, and ameliorates PAH in this model; these original studies demonstrate a relationship between Treg deficiency and the proclivity for PAH. In SU5416-treated athymic rats, activated macrophages expand and produce leukotriene B\(_4\) (LTB\(_4\)) in a lung environment lacking Tregs. This eicosanoid may contribute to pulmonary vascular disease by inducing endothelial cell apoptosis/transformation, smooth muscle cell proliferation/hypertrophy, and adventitial fibroblast proliferation/migration (83, 88). Interestingly, unlike some animal models which observe PAH more consistently in males, the Treg-deficient rat model shows a profoundly heightened vulnerability to disease in both sexes. In the future, other PAH models (currently in development), with more subtle Treg deficits than the athymic rat, will provide greater opportunities to understand the unique participation of Tregs in pulmonary vascular health and disease.

**TREGS AND SEX-RELATED PATHOLOGY IN PAH**

PAH disproportionately affects women more than men (89). Our recent athymic rat study highlights the effect of sex on Treg activities in PAH and suggests the Tregs’ dominant role in protecting females against this condition (22). Treg sexual dimorphism is a complex subject. While males have a larger thymus, higher Treg numbers, and more robust Treg immunosuppressive capacity, female hormones enhance Tregs’ growth and function (90, 91). Because PAH is worse in females in this Treg-deficient model, estrogen (17b-estradiol; E\(_2\)) may be exacerbating immunity in the absence of normal Treg function. E\(_2\) is a highly pleiotropic hormone for immune function, being both pro-inflammatory and anti-inflammatory under different conditions and with varying types of cells (92). E\(_2\) promotes Treg differentiation (93–96) while also enhancing Th2 responses (97) and B cell/macrophage activation (98–100). Treg suppressive activity involves E\(_2\)-dependent expression of the anti-inflammatory checkpoint molecule Programmed Death-1 (PD-1) (96). Cumulatively, these findings raise the seemingly divergent possibilities that E\(_2\) may promote protective Treg function and that E\(_2\) can intensify harmful immunity (Figure 1). Because E\(_2\) supplementation may be a possible therapeutic strategy in PAH (84), it is crucial to discern the molecular underpinnings of E\(_2\) in PAH immune injury. Finally, PAH is prevalent in obese women (101). Tregs are decreased in adipose tissue, a phenomenon that may contribute to persistent low-grade inflammation. Reduced Tregs, expressing adiponectin receptor 1, in the lungs of obese mice promotes inflammation and a predisposition to PAH (79).

In the absence of Tregs, female PAH rat lungs exhibit worse hemodynamics, increased macrophage infiltration, a more

**TABLE 1 | Clinical and pre-clinical studies show a relationship between Treg abnormalities and PAH-associated conditions.**

| PAH-associated conditions | PAH prevalence | Treg (T cell) abnormalities |
|--------------------------|----------------|-----------------------------|
| Clinical Studies         |                |                             |
| Scleroderma              | 10% (50)       | ↓Treg function and frequency (51) |
| Lupus erythematosus      | 3%-23% (52)    | Altered Treg frequency, ↓Treg/Teff ratio (57) |
| Sjögren’s syndrome       | 10% (54)       | Altered Treg frequency, ↓Treg/Th17 (55) |
| Polyomysitis             | 10% (56)       | ↓Treg frequency and ↓Treg/Teff ratio (57) |
| Antiphospholipid syndrome| 10% (58)       | ↓Treg frequency and ↓Treg/Teff ratio (59) |
| Hashimoto’s thyroiditis  | 10% (56)       | ↓Treg/Teff ratio and ↓Treg function (51) |
| HIV infection            | 5%-15% (60)    | Altered Treg frequency, phenotype, and function (53) |
| Schistosomiasis          | 5%-25% (61)    | Altered Treg frequency (55) |
| Herpesvirus B            | 3% (66)        | Altered Treg frequency and function (57) |
| D'George syndrome       | case reports (68, 69) | Abnormal thymic Treg development (70) |
| IPEX syndrome           | case report (ATS) (71) | FOXP3 mutations and Treg defects (72) |
| APS-1                    | case report (73) | ARE mutations and Treg defects (74) |
| Idiopathic PAH           | n/a            | ↓Treg/Th17 (75) |
| CTD-PAH                  | n/a            | ↓Treg frequency, ↓Treg/Teff ratio and ↓Treg function (36) |
| Pre-clinical             |                |                             |
| Athymic rats             | 100% after SU5416 | ↓Treg causes PAH (w/o hypoxia), Treg reconstitution protects rats from PAH |
| B6 mice                  | 100% after hypoxia | Treg infusion protects mice against PAH (76) |
significant decline in right ventricular (RV) capillary density, and greater RV perivascular and interstitial fibrosis (22). Treg infusion mitigates PAH and prevents these pathologic changes. Further, prostacyclin (PGI₂), a potent vasodilator, is decreased in females with PAH and may also contribute to the sex-related differences. Following vascular injury and Treg therapy, PGI₂ blood levels increase dramatically. Cyclooxygenase-2 (COX-2) and PGI₂ synthase (PTGIS), critical enzymes for PGI₂ synthesis, are profoundly upregulated in the lungs of Treg-treated rats. Blocking COX-2, heme oxygenase-1 (HO-1), and Programmed Death Ligand-1 (PD-L1)/PD-1 signaling pathways abrogate Treg protection from PAH (22). Thus, in the absence of regular Treg activity, reduced pulmonary COX-2/PTGIS expression and serum PGI₂ levels correlate with worse disease in females. For these reasons, Treg therapy holds promise for PAH patients by helping them restore PGI₂ production in their affected lung tissue. Presently, how Tregs promote PGI₂ synthesis in the major endothelial cell production sites is unknown.

Pulmonary arteries and RV capillaries remodel in evolving PAH (102). Treg infusion into T cell-deficient rats, treated with SU5416, do not develop pulmonary vascular disease and show increased expression of COX-2, PTGIS, HO-1, and PD-L1 in the smooth muscle cell layer of pulmonary arterioles. The Treg-protected RV, by distinction, demonstrates increased expression of these protective molecules in cardiac intimal cells and myocardium (22). Treg therapy may additionally afford protection in PAH by upregulating vascular wall BMPR2 (Figure 2). In vitro, Tregs cocultured with cardiac endothelial cells increase the expression of COX-2, PTGIS, HO-1, PD-L1, PGI₂, interleukin-10 (IL-10), and estrogen receptors [64-fold for estrogen receptor-alpha (ER-α) and 22-fold for ER-beta (ER-β)]. Collectively, data from this latter study suggest that Tregs protect against RV injury through augmented biosynthesis of ERs, COX-2, HO-1, PGI₂, and IL-10 in cardiac vascular endothelial cells; this activity points to a homeostatic endothelial cell-Treg interaction.

AN EMERGING RATIONALE FOR TREG THERAPY TO TREAT PAH

Treg cell therapy holds treatment promise for a variety of conditions (103, 104). Purified Tregs from the patient’s blood are expanded, conditioned, and infused back into the donor’s circulation. Prior studies support the rationale for now developing Treg immunotherapy protocols as a treatment for clinical PAH. This effort will benefit from 1) understanding how infused Tregs home to lungs and draining lymph nodes, 2) discerning how Tregs contribute to vascular repair with more established pulmonary vascular disease, and 3) developing strategies to expand Tregs ex vivo while enhancing their activities and stability. Relatively small numbers of Tregs are needed to prevent PAH in rats, but their efficacy with these low numbers diminishes if administered after the disease has progressed (21). Existing literature suggests that the infusion of logarithmically increased numbers of Tregs substantially empowers the treatment effect in established disease (105) and could do so for PAH. More than 50 Treg-infusion clinical trials are being tested for autoimmune and inflammatory diseases (103, 104). Co-medication of IL-2, IL-7, or IL-33 promotes Treg survival and proliferation after cell transfer, and strategies that increase FOXP3 expression improve Treg persistence and suppressive function (103). Increasing Treg specificity is promoted through genetic engineering that enhances chimeric antigen receptors (CAR) expression in Tregs (106). However, to date, there are no consistent antigen targets for PAH, and polyclonal Treg infusions may be the most feasible starting approach.
FIGURE 2 | The role of Tregs in PAH. In Treg-deficient rats, vascular injury culminates in enhanced B cell and macrophage-dominated inflammation. With Treg infusion before the induction of vascular injury, PAH is avoided through upregulation of anti-inflammatory and vasoprotective pathways, which include upregulation of COX2, PGIS, and BMPR2.
CONCLUSIONS

Treg dysfunction is a feature of PAH and contributes to immune dysregulation observed in the disease (9, 107). A unique theme of the research presented in this mini-review is that Tregs can directly afford protection to vascular cells, in addition to its better-studied anti-inflammatory effect on other immune cells. In an athymic rat model treated with SU5416 to induce pulmonary vascular injury, Treg infusion also protected right heart function. Sexual differences are present in various PAH manifestations. Consequently, the study of how regulatory immunity differentially impacts men and women with this condition continues to be an area of promising investigation. Combining immune modulators with vasodilators offers potentially better treatment for PAH. Such an approach was recently taken with a randomized multi-center placebo-controlled clinical trial testing B cell depletion with rituximab to treat systemic sclerosis-associated PAH (108); therapy was safe and potentially effective as an adjunct to standard-of-care vasodilators. For this reason, as Treg therapy becomes a therapeutic option for a variety of immunological disorders (109, 110), vulnerable PAH patients represent a new and promising target population.

AUTHOR CONTRIBUTIONS

All authors (WT, SJ, XJ, RT, DK, TG, SA, SP, NV, QT, and MN) contributed to the design, writing and review of this mini review. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by National Institutes of Health grants HL014985, HL122887, and HL138473 to MN.

REFERENCES

1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic Definitions and Updated Clinical Classification of Pulmonary Hypertension. Eur Respir J (2019) 53(1):1801913. doi: 10.1183/13993003.01913-2018
2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol (2013) 62(25 Suppl):D34–41. doi: 10.1016/j.jacc.2013.10.029
3. Machado RD, Southgate I, Eichstaedt CA, Aldred MA, Austin ED, Best DH, et al. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat (2015) 36(12):1113–27. doi: 10.1002/humu.22904
4. Humbert M, Sitbon O, Chausot A, Bertocci M, Halib G, Gressin V, et al. Pulmonary Arterial Hypertension in France: Results From a National Registry. Am J Respir Crit Care Med (2006) 173(9):1023–30. doi: 10.1164/rccm.200510-1668OC
5. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary Arterial Hypertension: Basis of Sex Differences in Incidence and Treatment Response. Br J Pharmacol (2014) 171(3):567–79. doi: 10.1111/bph.12281
6. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex Differences in the Diagnosis, Treatment, and Outcome of Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early Differences in the Diagnosis, Treatment, and Outcome of Patients With Pulmonary Hypertension. Circulation (2015) 132(1):53–60. doi: 10.1161/CIRCULATIONAHA.114.012977
7. Shevyrev D, Tereshchenko V. Treg Heterogeneity, Function, and Homeostasis. Front Immunol (2019) 10:3100. doi: 10.3389/fimmu.2019.01578
8. Tamosiuniene R, Dzeroshchenko V. Treg Heterogeneity, Function, and Homeostasis. Front Immunol (2019) 10:3100. doi: 10.3389/fimmu.2019.01300
9. Nicolls MR, Tarasveciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and Pulmonary Hypertension: A Perspective. Eur Respir J (2005) 26(6):1110–8. doi: 10.1183/09031936.05.0045705
10. Andruska E, Spiekerkoetter E. Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension. Int J Mol Sci (2018) 19(9):2499. doi: 10.3390/ijms19092499
11. Zais D, Minutti CM, Knipper JA. Immune- and Non-Immune-Mediated Roles of Regulatory T-Cells During Wound Healing. Immunology (2019) 157(3):190–7. doi: 10.1111/imn.13657
12. Arpaia N, Green JA, Molledo B, Arvey A, Hemmers S, Yuan S, et al. A Distinct Function of Regulatory T Cells in Tissue Protection. Cell (2015) 162(5):1078–89. doi: 10.1016/j.cell.2015.08.021
13. Vignali DA, Collison LW, Workman CJ. How Regulatory T Cells Work. Nat Rev Immunol (2008) 8(7):523–32. doi: 10.1038/nri2343
14. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T Cells and Immune Tolerance. Cell (2008) 135(5):775–87. doi: 10.1016/j.cell.2008.05.009
15. Ramsdell F, Ziegler SF. FOXP3 and Scurfy: How it All Began. Nat Rev Immunol (2014) 14(3):343–9. doi: 10.1038/nri3650
16. Zhao H, Liao X, Kang Y. Tregs: Where We Are and What Comes Next? Front Immunol (2017) 8:1578. doi: 10.3389/fimmu.2017.01578
17. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circ Res (2014) 115(1):165–75. doi: 10.1161/CIRCRESAHA.113.301141
18. Trammell AW, Shah AJ, Phillips LS, Michael Hart C. Mortality in US Veterans With Pulmonary Hypertension: A Retrospective Analysis of Survival by Subtype and Baseline Factors. Pulm Circ (2019) 9 (1):2045894019825763. doi: 10.1177/2045894019825763
Tian et al. Tregs and Pulmonary Arterial Hypertension

Eur J Immunol (2014) 44(4):3459–66. doi: 10.1002/eji.201343783

45. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T Cells Prevent Catastrophic Autoimmune Dysfunction. J Immunol (2010) 184(2):917–25. doi: 10.4049/jimmunol.1001795

46. Huertas A, Phan C, Bordenave J, Tu L, Thilliet R, Le Hirre M, et al. Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest (2016) 149(6):1482–93. doi: 10.1016/j.chest.2016.01.004

47. Sada Y, Dohi Y, Uga S, Higashi T, Kinoshita H, Kihara Y. Non-Suppressive Regulatory T Cell Subset Expansion in Pulmonary Arterial Hypertension. Heart Vessels (2016) 31(8):1319–26. doi: 10.1007/s00380-015-0772-4

48. Ulrich S, Nicolli MR, Taraseviciene L, Speich R, Voelkel N. Increased Regulatory and Decreased CD8+ Cytotoxic T Cells in the Blood of Patients With Idiopathic Pulmonary Arterial Hypertension. Respiration (2008) 75(3):272–80. doi: 10.1007/s00119-008-2396-3

49. Jasiewicz M, Moniuszko M, Pawłak D, Knapp M, Rusak M, Kazimierzczuk R, et al. Activity of the Kynurenine Pathway and its Interplay With Immunity in Patients With Pulmonary Arterial Hypertension. Heart (2016) 102(3):230–7. doi: 10.1136/heartjnl-2015-308581

50. Chaisson NF, Hassoun PM. Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Chest (2013) 144(4):1346–56. doi: 10.1378/chest.12-2396

51. Frantz C, Auffray C, Avouac J, Allanore Y. Regulatory T Cells in Systemic Sclerosis. Front Immunol (2018) 9:2356. doi: 10.3389/fimmu.2018.02356

52. Xia YK, Tu SH, Hu YH, Wang Y, Chen Z, Day HT, et al. Pulmonary Hypertension in Systemic Lupus Erythematosus: A Systematic Review and Analysis of 642 Cases in Chinese Population. Rheumatol Int (2013) 33(5):1211–7. doi: 10.1007/s00296-012-2525-y

53. Suen JL, Chang BL. CD4(+)FoxP3(+) Regulatory T-Cells in Human Systemic Lupus Erythematosus. J Formos Med Assoc (2012) 111(9):465–70. doi: 10.1016/j.jfma.2012.05.013

54. Sato T, Hatano M, Iwasaki Y, Maki H, Saito A, Minatsuji S, et al. Prevalence of Primary Sjogren’s Syndrome in Patients Undergoing Evaluation for Pulmonary Arterial Hypertension. PloS One (2018) 13(5):e0197297. doi: 10.1371/journal.pone.0197297

55. Alunno A, Carubbi F, Bistoni O, Bartoloni E, Mirabelli G, et al. T Regulatory Cell Levels Decrease in People Infected With Schistosoma Mansoni on Effective Treatment. J Immunol (2014) 192(5):1628–31. doi: 10.1016/j.jimmuni.2014.05.007

56. Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC, Lung HIVS. Regulatory T-Cell Function in Autoimmune Thyroid Disease. Thyroid (2015) 25(8):923–30. doi: 10.1089/thy.2014.0186

57. Zhang SX, Wang J, Sun HH, Zhang JQ, Liu GY, Luo J, et al. Circulating Regulatory T Cells Are Absent in Patients With Primary Antiphospholipid Syndrome. Arthritis Rheum (2018) 70(5):758–67. doi: 10.1002/art.40316

58. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN. Impairment of CD4+ and CD8+ T-Cell Function in Patients With Primary Antiphospholipid Syndrome. J Clin Immunol (2013) 33(3):285–92. doi: 10.1007/s10875-012-9857-y

59. Ulrich S, Picard A, Choonkittirodkul N, Assaf Y, Alzate S, Bottinger EP, et al. Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation. J Immunol (2017) 188(12):2573–9. doi: 10.4049/jimmunol.162.1.259

60. Hsue PY, Morelli J, Huang L, Flores SC, Lung HIVS. Regulatory T-Cell Function in Autoimmune Thyroid Disease. Thyroid (2015) 25(8):923–30. doi: 10.1089/thy.2014.0186

61. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN. Impairment of CD4+ and CD8+ T-Cell Function in Patients With Primary Antiphospholipid Syndrome. J Clin Immunol (2013) 33(3):285–92. doi: 10.1007/s10875-012-9857-y

62. Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC, Lung HIVS. Regulatory T-Cell Function in Autoimmune Thyroid Disease. Thyroid (2015) 25(8):923–30. doi: 10.1089/thy.2014.0186

63. Lopez-Abente J, Correa-Rocha R, Pion M. Functional Mechanisms of Treg Cells in Systemic Lupus Erythematosus. J Formos Med Assoc (2012) 111(9):465–70. doi: 10.1016/j.jfma.2012.05.013

64. Papamatheakis DG, Mocumbi AO, Kim NH, Mandel J. Schistosomiasis-Associated Pulmonary Hypertension. Chest (2016) 149(6):1482–93. doi: 10.1016/j.chest.2016.01.004

65. Sada Y, Dohi Y, Uga S, Higashi T, Kinoshita H, Kihara Y. Non-Suppressive Regulatory T Cell Subset Expansion in Pulmonary Arterial Hypertension. Heart Vessels (2016) 31(8):1319–26. doi: 10.1007/s00380-015-0772-4

66. Nicastri E, Vizza CD, Carletti F, Cicalini S, Badagliacca R, Poscia R, et al. Human Herpesvirus 8 and Pulmonary Hypertension. Emerg Infect Dis (2005) 11(9):1480–2. doi: 10.3201/eid1109.0408801480
Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. *Am J Respir Crit Care Med* (2021) 204(2):209–221. doi: 10.1164/rccm.202009-3481OC

109. Tang Q, Bluestone JA. Regulatory T-Cell Therapy in Transplantation: Moving to the Clinic. *Cold Spring Harb Perspect Med* (2013) 3(11): a015552. doi: 10.1101/cshperspect.a015552

110. Singer BD, King LS, D’Alessio FR. Regulatory T Cells as Immunotherapy. *Front Immunol* (2014) 5:46. doi: 10.3389/fimmu.2014.00046

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Tian, Jiang, Tamosiuniene, Kim, Guan, Arsalane, Pasupneti, Voelkel, Tang and Nicolls. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.